PubMed Health⌕ Search

Biomedical subjects

A De Renzo

Publications and source records attributed to A De Renzo.

At least 19 recordsLinked to original sources
PubMed1990

Induction of alkaline phosphatase activity in chronic myeloid leukemia cells: in vitro studies and speculative hypotheses.

Three patients with Ph chromosome + chronic myeloid leukemia (CML) in chronic phase suffered from intercurrent pleuritis of undefined origin. At that time, leucocyte alkaline phosphatase activity (LAPA) score was low for circulating neutrophils, but high for those from pleural effusion. LAP negative circulating CML granulocytes were incubated with the pleural liquid: after 40-70 hr, almost all were intensely LAP positive. This finding suggests that the low LAPA score in resting CML neutrophils is attributable to the absence of appropriate stimuli rather than to an incapacity to synthesize the enzyme.

Alkaline Phosphatase↗
PubMed1981

[Effect of pulmonary reventilation on gas exchange after cryolytic removal of obstruction in endobronchial tumors].

Blood gas analysis was used to assess the value of cryolytic endobronchial disobstruction in functional recovery of the reventilated lung parenchyma, with particular reference to the real improvement brought about in blood gas equilibrium by reventilation. Blood gas analysis was carried out in 5 cases of malignant tracheobronchial neoplasia (3 with atelectasis or subatelectasis) before and after disobstruction. Improved gas exchange, primarily in the form of better blood oxygen values, was noted in all cases, with a mean improvement of 28% in 3 cases and 7% in 2. It should be noted, however, that there was no correspondence between the results and the presence or otherwise of radiological evidence of atelectasis prior to the treatment.

Aged↗
PubMedDate not supplied

Treatment of Waldenstrom's macroglobulinemia with interferon.

Three patients suffering from Waldenström's disease were treated with recombinant human alpha 2b interferon (INTRON-A, Shering-Essex) as single agent (3 megaU every day or three times a week). After four months of treatment, a striking reduction of serum IgM with normalization of the electrophoretic profile was seen in one patient (who had been splenectomized and intensely pretreated with chemotherapy); IgM was about halved in the remaining two patients. With the lower dosage, tolerance was excellent in all cases. Interferon treatment has to be considered in the management of macroglobulinemia.

Adult↗
PubMedDate not supplied

Alpha interferon in the treatment of chronic myelomonocytic leukemia.

This study aimed at evaluating the effectiveness of alpha interferon (IFN) in chronic myelomonocytic leukemia, a disease for which therapeutic options are still unsatisfactory. Fourteen sequential unselected patients received recombinant alpha-2b IFN (Intron-A, Schering-Essex) 3 megaU/day, progressively elevated to 10 megaU/day in non responders. Rate and type of response were evaluated in the 10 patients who completed a minimum treatment period of three months. Monocytosis, present in all patients by definition, was reduced in 8 of these 10; neutrophils decreased in 5 of 7 patients with high initial values. Signs of ineffective hemopoiesis were generally not influenced by the treatment, nor were organomegaly and hypergammaglobulinemia, when present; however, in 4 patients the Hb level improved with treatment. IFN treatment failed to improve in vitro growth of GM colonies, but there was improvement of the cluster/colony ratio, due to decrease number of clusters. Lysozyme production by pathologic monocytes was inhibited in the presence of IFN in vitro. Tolerance was variable: three patients interrupted the treatment for unmanageable side effects. These results show that alpha IFN can be effective in CMML patients with prominent proliferative aspects.

Aged↗